Kugelmeiers Ltd. was founded in 2015 as a spin-off from the University of Zurich in Switzerland.
The company originated from the University Hospital of Zurich’s human islet cell transplantation clinical program for the treatment of diabetes. The core business is the translation of novel insights of biological realities of cells into products that are optimally suited for 3D cell culture and cell transplantation. The company’s expertise in cell transplantation, 3D cell culture and stem cell biology addresses an increasingly growing market.
In order to drive the development of promising future cell therapies, Kugelmeiers Ltd. cooperates with leading scientists, institutes, laboratories and industry partners worldwide.
For more information please visit our company page: